Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16595716 | 0.95 | MAPT (0.47) | MAPTSMN1; SMN2KMT2AMEN1CASP3 | |
| SCHEMBL13199136 | 0.93 | TSHR (0.49) | LMNACYP1A2NPSR1MAPK1TSHR | |
| SCHEMBL5003336 | 0.87 | NPSR1 (0.47) | MAPTSMN1; SMN2KMT2ALMNANPSR1 | |
| SCHEMBL17583195 | 0.87 | NPSR1 (0.51) | MAPTKMT2AMEN1CYP1A2CYP2C9 | |
| SCHEMBL13199166 | 0.87 | TSHR (0.46) | MAPTKMT2AMEN1LMNANPSR1 | |
| SCHEMBL31306426 | 0.86 | CA12 (0.55) | MAPTKMT2ATSHRGAATDP1 | |
| SCHEMBL24614580 | 0.84 | LMNA (0.56) | MAPTSMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL2879531 | 0.84 | CA1 (0.58) | MAPTSMN1; SMN2KMT2AMEN1CASP3 | |
| SCHEMBL19183403 | 0.84 | MAPT (0.49) | MAPTSMN1; SMN2KMT2AMEN1CASP3 | |
| SCHEMBL8258321 | 0.84 | TSHR (0.55) | MAPTSMN1; SMN2KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731634-A1 | SMALL-MOLECULE STABILIZERS OF THE CHREBP 14-3-3 INTERACTION | Technische Universiteit Eindhoven (NL) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025005795-A1 | SMALL-MOLECULE STABILIZERS OF THE CHREBP 14-3-3 INTERACTION | TECHNISCHE UNIVERSITEIT EINDHOVEN (NL) | 2025-01-02 | — | — | WO | disclosed |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-12-26 | — | — | US | disclosed |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-08 | — | — | US | disclosed |
| EP-4364737-A2 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4229056-B1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-04 | — | — | US | disclosed |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-09-26 | — | — | US | disclosed |
| EP-4229056-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022086828-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-106715435-A | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | 卢郡控股(开曼)有限公司 | 2017-05-24 | — | — | CN | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-9567341-B2 | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2017-02-14 | — | — | US | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-03-17 | — | — | US | disclosed |
| US-8013186-B2 | Haloalkyl containing compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090023781-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | VIROBAY, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1817275-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006060494-A1 | HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023781-A1 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors | CTSF, CTSS, CTSE | MAPT 3153/4885SMN1; SMN2 4865/4885KMT2A 4029/4885 |
| US-20240109888-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | MAPT 2553/4885SMN1; SMN2 4117/4885KMT2A 2486/4885 |
| US-11767322-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | MAPT 2553/4885SMN1; SMN2 4117/4885KMT2A 2486/4885 |
| US-12110290-B2 | Triazolopyridinyl compounds as kinase inhibitors | RIPK1, RIPK3, RIPK4 | MAPT 2553/4885SMN1; SMN2 4117/4885KMT2A 2486/4885 |
| US-20240425505-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | MAPT 2553/4885SMN1; SMN2 4117/4885KMT2A 2486/4885 |
| US-20160075713-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN1, GRIN2A, GRIN2B | MAPT 3030/4885SMN1; SMN2 3078/4885KMT2A 1080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.